News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MGI PHARMA, INC. (MOGN) Announces Results from Study Involving the Dual Implantation of GliadelĀ® Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiforme


1/18/2008 9:14:08 AM

MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that study results published in the February issue of the Journal of Neurosurgery show that treatment of patients who have recurrent glioblastoma multiforme (GBM) with both GliadelĀ® Wafer and radioactive seeds (iodine-125) at the time of tumor resection, may provide for a better outcome than treatment of patients with surgery and either agent alone.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES